We are live on ! Find out more
WVP

Worth Venture Partners Portfolio holdings

AUM $31.6M
1-Year Est. Return 28.5%
This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
AUM
$184M
AUM Growth
-$21.4M
Cap. Flow
-$46.6M
Cap. Flow %
-25.37%
Top 10 Hldgs %
35.95%
Holding
217
New
29
Increased
61
Reduced
33
Closed
50

Top Buys

Rank Stock Value
1
MCHP icon
Microchip Technology
MCHP
+$5.09M
2
GSIT icon
GSI Technology
GSIT
+$2.17M
3
ANVS icon
Annovis Bio
ANVS
+$1.48M
4
CLNN icon
Clene
CLNN
+$1.45M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.28M

Sector Composition

Rank Sector Weight
1 Technology 18.84%
2 Healthcare 16.62%
3 Financials 6.45%
4 Real Estate 2.82%
5 Consumer Staples 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MREO
151
Mereo BioPharma
MREO
$54.7M
-76,513
Closed -$54.1K
MRK icon
152
Merck
MRK
$322B
-12,900
Closed -$1.37M
MRK icon
153
PUT
Merck
MRK
$322B
-12,900
Closed -$5.68K
NBIX icon
154
Neurocrine Biosciences
NBIX
$16.8B
-6,393
Closed -$647K
NBIX icon
155
PUT
Neurocrine Biosciences
NBIX
$16.8B
-12,800
Closed -$4.48K
NOK icon
156
Nokia
NOK
$51B
-20,000
Closed -$98.2K
NRDY icon
157
Nerdy
NRDY
$106M
-98,400
Closed -$411K
NVCR icon
158
CALL
NovoCure
NVCR
$1.73B
-25,600
Closed -$25.9K
NVCR icon
159
NovoCure
NVCR
$1.73B
-6,400
Closed -$385K
PFE icon
160
Pfizer
PFE
$143B
-25,700
Closed -$1.05M
PFE icon
161
PUT
Pfizer
PFE
$143B
-25,700
Closed -$2.57K
PRAX icon
162
Praxis Precision Medicines
PRAX
$8.58B
-854
Closed -$10.4K
PTCT icon
163
PTC Therapeutics
PTCT
$5.64B
-8,956
Closed -$434K
PTCT icon
164
PUT
PTC Therapeutics
PTCT
$5.64B
-12,800
Closed -$63.4K
RCUS icon
165
Arcus Biosciences
RCUS
$3.55B
-12,700
Closed -$242K
SCYX icon
166
SCYNEXIS
SCYX
$48.1M
-35,666
Closed -$856K
SILC icon
167
Silicom
SILC
$229M
-74,896
Closed -$2.81M
SRPT icon
168
PUT
Sarepta Therapeutics
SRPT
$1.57B
-12,800
Closed -$156K
WOLF icon
169
Wolfspeed
WOLF
$1.23B
-6,111
Closed -$397K
YMAB
170
DELISTED
Y-mAbs Therapeutics
YMAB
-104,487
Closed -$523K
DM
171
DELISTED
Desktop Metal, Inc.
DM
-18,450
Closed -$424K
INFN
172
DELISTED
Infinera Corporation Common Stock
INFN
-114,534
Closed -$889K
SIX
173
DELISTED
Six Flags Entertainment Corp.
SIX
-8,669
Closed -$232K
PRTK
174
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
-657,885
Closed -$1.67M
AMRS
175
CALL
DELISTED
Amyris Inc.
AMRS
-172,400
Closed -$32.5K

Similar funds

Worth Venture Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Worth Venture Partners held 217 positions worth $184M, down 10% from $205M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Worth Venture Partners withdrew a net $46.6M in Q2 2023, closing 50 positions and reducing 33 holdings. Its most notable exit was Adtran, an estimated $4.21M position sold in full.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Worth Venture Partners opened a new position in GSI Technology worth $2.76M.

  • Worth Venture Partners's largest Q2 2023 buy was GSI Technology: 499,400 shares worth $2.76M.
  • Worth Venture Partners added most to Microchip Technology in Q2 2023, an estimated $5.09M increase.
  • Worth Venture Partners's biggest Q2 2023 reduction was Marinus Pharmaceuticals, Inc, cutting an estimated $2.59M.
  • Worth Venture Partners fully exited Adtran in Q2 2023, selling an estimated $4.21M.
  • Worth Venture Partners's ten largest holdings make up 36% of its $184M portfolio in Q2 2023.
  • Worth Venture Partners opened 29 new positions and closed 50 in Q2 2023.
  • Worth Venture Partners's portfolio value fell 10% quarter-over-quarter to $184M.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.